GKOS: Repeat Dosing And Long Dated Guidance Will Shape Demand Expectations

Glaukos' updated fair value estimate moves from $138.75 to about $151.08 as analysts factor in higher long term profit margin assumptions, a modestly higher discount rate, slightly tempered revenue growth expectations, and a lower future P/E in light of recent price target increases from firms across the Street.

Analyst Commentary

Recent Street research around Glaukos centers on updated price targets that reflect a mix of confidence in the product ramp story and some caution around execution risk and long term expectations. Here is how that sentiment breaks down.

Bullish Takeaways

Bullish analysts are lifting price targets in increments of about US$5 to US$10, which signals that updated models support a higher fair value range as assumptions on margins and product ramp are refined.
Q4 revenue came in line with the earlier preannouncement, which gives analysts more confidence that management guidance and internal forecasts are being executed without major surprises.
iDose is described as continuing to ramp, with potential re administration starting to contribute more meaningfully in the second half of the year. Bullish analysts see this as supporting a multi year volume build and the case for durable growth.
Some bullish analysts point to management commentary around Epioxa volume ramping back to prior Photrexa peaks by 2030. They translate this into a potential opportunity that could exceed US$1b, which in their models supports long term growth optionality.

Bearish Takeaways

Even as price targets move higher, analysts are tempering long term revenue growth assumptions. This suggests that expectations are being kept in check and that execution over multiple years remains a key watch point.
The focus on re administration for iDose and on Epioxa volumes reaching prior Photrexa levels highlights product concentration risk, since a meaningful portion of the long term thesis depends on these treatment ramps playing out as expected.
The emphasis on guidance out to 2026 and volume ambitions through 2030 underscores the long dated nature of parts of the thesis. This can introduce uncertainty around actual uptake, reimbursement, and competitive dynamics over time.
Analysts referencing a very large Epioxa opportunity also implicitly raise the bar for execution, since any shortfall versus these high level volume aspirations could put pressure on premium valuation multiples and future target prices.

What’s in the News

Glaukos raised its 2026 net sales guidance to a range of US$620 million to US$635 million, up from the prior range of US$600 million to US$620 million, signaling updated expectations for the top line in that year (Corporate guidance).
The company issued initial 2026 net sales guidance at US$600 million to US$620 million, framing the revenue outlook that subsequent guidance revisions build on (Corporate guidance).
Glaukos reported an impairment of intangible asset of US$112,867,000 for the fourth quarter ended 31 December 2025, which affects reported earnings for that period (Impairment/write off).
Epioxa is now commercially available in the U.S. through Glaukos and its specialty pharmaceutical distribution network for the treatment of keratoconus, using a topical, incision free corneal cross linking approach supported by patient access, assistance, and awareness programs (Product related announcement).
The U.S. Centers for Medicare and Medicaid Services assigned a permanent HCPCS J code, J2789, for Epioxa for keratoconus treatment, effective 1 July 2026, which is expected to streamline billing and reimbursement over time for healthcare providers and payers (Product related announcement).

Valuation Changes

Fair Value has risen moderately, moving from $138.75 to about $151.08 per share.
Discount Rate has inched higher, shifting from 7.70% to about 7.80%, implying a slightly higher required return in the updated model.
Revenue Growth assumption is slightly lower, moving from about 26.06% to roughly 25.43% in the long-term outlook.
Net Profit Margin has been lifted, increasing from about 9.75% to roughly 10.50%, which raises the earnings power embedded in the forecast.
Future P/E has been marked down, moving from about 104.88x to roughly 96.11x, indicating a lower valuation multiple applied to projected earnings.

4 views

Key Takeaways

Innovative glaucoma therapies and global expansion efforts position the company for sustained revenue growth and reduced reliance on a single product.
Emphasis on minimally invasive solutions and payer adoption strengthens long-term profitability and supports increased market share.
Market share and profit growth are threatened by rising competition, reimbursement challenges, product launch risks, high investment costs, and external healthcare policy headwinds.

Catalysts

About Glaukos

An ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies-a substantial long-term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi-year revenue and market expansion.
Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.
Global scaling of commercial and market access teams, international infrastructure expansion, and upcoming launches in underpenetrated markets (such as the EU clearance and launch of iStent infinite) are expected to drive increased international sales, supporting double-digit revenue growth and further margin leverage through operational efficiencies.
Increasing penetration into payer coverage for iDose (with 50%+ of commercial/Medicare lives already covered and others expected to follow) and ongoing margin improvement from higher iDose mix (83% gross margin in Q2) support the potential for sustained net margin and earnings growth as reimbursement solidifies and the product mix shifts toward higher-margin, minimally invasive solutions.
The accelerating migration toward minimally invasive and in-office procedures (e.g., iDose TR, future office-based versions) aligns with the broad medical trend favoring lower-risk, outpatient therapies; this is expected to drive enduring physician and patient adoption, increase procedure volume, and improve utilization rates while also potentially reducing cost pressures and enhancing profitability longer term.

Glaukos Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Glaukos's revenue will grow by 25.4% annually over the next 3 years.
Analysts assume that profit margins will increase from -34.3% today to 10.5% in 3 years time.
Analysts expect earnings to reach $114.2 million (and earnings per share of $1.85) by about May 2029, up from -$189.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $162.4 million in earnings, and the most bearish expecting $57.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 97.3x on those 2029 earnings, up from -43.5x today. This future PE is greater than the current PE for the US Medical Equipment industry at 23.6x.
Analysts expect the number of shares outstanding to grow by 0.7% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing competition from both established device makers and new entrants in the minimally invasive glaucoma surgery (MIGS) and procedural pharmaceutical space may erode Glaukos' market share, which creates risk to long-term revenue growth and top-line expansion.
The company is exposed to ongoing and potential future reimbursement pressure-including possible cuts to physician fees for ophthalmic procedures from CMS and slow professional fee adoption by certain key Medicare Administrative Contractors (MACs)-which could negatively impact pricing power, procedure volumes, and net margins.
Adverse or delayed outcomes in clinical trials, regulatory reviews, or product launches (e.g., delayed FDA reimplantation decision for iDose, transition from Photrexa to Epioxa, or slower than expected rollout of new devices) could disrupt anticipated revenue streams and weigh on earnings into the medium term.
The heavy investment required for R&D, marketing, advocacy, operating infrastructure, and international expansion, combined with methodical and sometimes unpredictable payer and reimbursement uptake, may constrain margin and operating leverage, potentially limiting net cash flow generation and profitability.
Secular risks such as potential healthcare cost-containment policy, shifts in CMS reimbursement methodologies, or global macroeconomic instability could reduce demand for elective and interventional ophthalmic procedures, introduce volatility to Glaukos' revenues, and hamper long-term profit growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $151.08 for Glaukos based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $170.0, and the most bearish reporting a price target of just $136.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $114.2 million, and it would be trading on a PE ratio of 97.3x, assuming you use a discount rate of 7.8%.
Given the current share price of $140.22, the analyst price target of $151.08 is 7.2% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Glaukos?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

GKOS: Momentum From Recent Regulatory Wins Will Drive Outperformance Through 2026